Inhibition of ISG15 Enhances the Anti-Cancer Effect of Trametinib in Colon Cancer Cells

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.v61:221296855
   PubMed Web of Science ®Google Scholar
• Oddo D, Sennott EM, Barault L, et al. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer. Cancer Res. 2016;76:4504–4515. doi:10.1158/0008-5472.CAN-16-039627312529
   PubMed Web of Science ®Google Scholar
• Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-Sulfate) capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 2010;16:1613–1623. doi:10.1158/1078-0432.CCR-09-248320179232
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23:5281–5293. doi:10.1200/JCO.2005.14.41516009947
   PubMed Web of Science ®Google Scholar
• Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22:4456–4462. doi:10.1200/JCO.2004.01.18515483017
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Solit DB. Resistance to MEK inhibitors: should we co-target upstream? Sci Signal. 2011;4:pe16. doi:10.1126/scisignal.200194821447797
   PubMed Web of Science ®Google Scholar
• Turke AB, Song Y, Costa C, et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012;72:3228–3237. doi:10.1158/0008-5472.CAN-11-374722552284
   PubMed Web of Science ®Google Scholar
• Britten CD. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol. 2013;71:1395–1409. doi:10.1007/s00280-013-2121-123443307
   PubMed Web of Science ®Google Scholar
• Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011;17:989–1000. doi:10.1158/1078-0432.CCR-10-220021245089
   PubMed Web of Science ®Google Scholar
• Infante JR, Papadopoulos KP, Bendell JC, et al. A phase 1b study of trametinib, an oral mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur J Cancer. 2013;49:2077–2085. doi:10.1016/j.ejca.2013.03.02023583440
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Bendell JC, Papadopoulos KP, et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol. 2015;26:58–64. doi:10.1093/annonc/mdu48225344362
   PubMed Web of Science ®Google Scholar
• Levine BD, Cagan RL. Drosophila lung cancer models identify trametinib plus statin as candidate therapeutic. Cell Rep. 2016;14:1477–1487. doi:10.1016/j.celrep.2015.12.10526832408
   PubMed Web of Science ®Google Scholar
• Xue Z, Vis DJ, Bruna A, et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018;28:719–729. doi:10.1038/s41422-018-0044-429795445
   PubMed Web of Science ®Google Scholar
• Manchado E, Weissmueller S, Morris JT, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016;534:647–651. doi:10.1038/nature1860027338794
   PubMed Web of Science ®Google Scholar
• Haas AL, Ahrens P, Bright PM, Ankel H. Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J Biol Chem. 1987;262:11315–11323.2440890
   PubMed Web of Science ®Google Scholar
• Bektas N, Noetzel E, Veeck J, et al. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res. 2008;10:R58. doi:10.1186/bcr211718627608
   PubMed Web of Science ®Google Scholar
• Desai SD, Wood LM, Tsai YC, et al. ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther. 2008;7:1430–1439. doi:10.1158/1535-7163.MCT-07-234518566215
   PubMed Web of Science ®Google Scholar
• Desai SD, Haas AL, Wood LM, et al. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res. 2006;66:921–928. doi:10.1158/0008-5472.CAN-05-112316424026
   PubMed Web of Science ®Google Scholar
• Padovan E, Terracciano L, Certa U, et al. Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. Cancer Res. 2002;62:3453–3458.12067988
   PubMed Web of Science ®Google Scholar
• Laljee RP, Muddaiah S, Salagundi B, et al. Interferon stimulated gene-ISG15 is a potential diagnostic biomarker in oral squamous cell carcinomas. Asian Pac J Cancer Prev. 2013;14:1147–1150. doi:10.7314/APJCP.2013.14.2.114723621203
   PubMedGoogle Scholar
• Chi LM, Lee CW, Chang KP, et al. Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS. Mol Cell Proteomics. 2009;8:1453–1474. doi:10.1074/mcp.M800460-MCP20019297561
   PubMed Web of Science ®Google Scholar
• Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer. 2006;94:1465–1471. doi:10.1038/sj.bjc.660309916641915
   PubMed Web of Science ®Google Scholar
• Roulois D, Loo YH, Singhania R, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162:961–973. doi:10.1016/j.cell.2015.07.05626317465
   PubMed Web of Science ®Google Scholar
• Ontology CG. The gene ontology (GO) project in 2006. Nucleic Acids Res. 2006;34:D322–D326. doi:10.1093/nar/gkj02116381878
   PubMed Web of Science ®Google Scholar
• Pitha-Rowe I, Petty WJ, Feng Q, et al. Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res. 2004;64:8109–8115. doi:10.1158/0008-5472.CAN-03-393815520223
   PubMed Web of Science ®Google Scholar
• D’Cunha J, Ramanujam S, Wagner RJ, Witt PL, Knight EJ, Borden EC. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol. 1996;157:4100–4108.8892645
   PubMed Web of Science ®Google Scholar
• Zhao C, Denison C, Huibregtse JM, Gygi S, Krug RM. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci USA. 2005;102:10200–10205. doi:10.1073/pnas.050475410216009940
   PubMed Web of Science ®Google Scholar
• Xu D, Zhang T, Xiao J, et al. Modification of BECN1 by ISG15 plays a crucial role in autophagy regulation by type I IFN/interferon. Autophagy. 2015;11:617–628. doi:10.1080/15548627.2015.102398225906440
   PubMed Web of Science ®Google Scholar
• Baldanta S, Fernandez-Escobar M, Acin-Perez R, et al. ISG15 governs mitochondrial function in macrophages following vaccinia virus infection. PLoS Pathog. 2017;13:e1006651. doi:10.1371/journal.ppat.100665129077752
   PubMed Web of Science ®Google Scholar
• Pitha-Rowe I, Hassel BA, Dmitrovsky E. Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. J Biol Chem. 2004;279:18178–18187. doi:10.1074/jbc.M30925920014976209
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR, Ishwaran H, Yoon T, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A. 2008;105:18490–18495. doi:10.1073/pnas.080924210519001271
   PubMed Web of Science ®Google Scholar
• Bogunovic D, Byun M, Durfee LA, et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science. 2012;337:1684–1688. doi:10.1126/science.122402622859821
   PubMed Web of Science ®Google Scholar
• Zhang X, Bogunovic D, Payelle-Brogard B, et al. Human intracellular ISG15 prevents interferon-alpha/beta over-amplification and auto-inflammation. Nature. 2015;517:89–93. doi:10.1038/nature1380125307056
   PubMed Web of Science ®Google Scholar
• Hadjivasiliou A. ISG15 implicated in cytoskeleton disruption and promotion of breast cancer. Expert Rev Proteomics. 2012;9:7. doi:10.1586/epr.12.36
   Web of Science ®Google Scholar
• Andersen JB, Hassel BA. The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe? Cytokine Growth Factor Rev. 2006;17:411–421. doi:10.1016/j.cytogfr.2006.10.00117097911
   PubMed Web of Science ®Google Scholar
• Desai SD, Reed RE, Burks J, et al. ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood). 2012;237:38–49. doi:10.1258/ebm.2011.01123622185919
   PubMed Web of Science ®Google Scholar
• Jeon YJ, Jo MG, Yoo HM, et al. Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15. J Clin Invest. 2012;122:2622–2636. doi:10.1172/JCI6176222706304
   PubMed Web of Science ®Google Scholar
• Brown AR, Simmen RC, Raj VR, Van TT, MacLeod SL, Simmen FA. Kruppel-like factor 9 (KLF9) prevents colorectal cancer through inhibition of interferon-related signaling. Carcinogenesis. 2015;36:946–955. doi:10.1093/carcin/bgv10426210742
   PubMed Web of Science ®Google Scholar
• Fan JB, Miyauchi-Ishida S, Arimoto K, et al. Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation. Proc Natl Acad Sci U S A. 2015;112:14313–14318. doi:10.1073/pnas.150569011226515094
   PubMed Web of Science ®Google Scholar